Potential herd protection against
Antimalarials
/ administration & dosage
Asymptomatic Diseases
/ epidemiology
Cluster Analysis
Humans
Malaria, Falciparum
/ drug therapy
Mass Drug Administration
Medication Adherence
/ statistics & numerical data
Myanmar
Plasmodium falciparum
/ isolation & purification
Rural Population
Spatio-Temporal Analysis
P. falciparum
elimination
epidemiology
global health
herd effect
human
infectious disease
mass drug administration
microbiology
plasmodium
spatial epidemiology
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
16 04 2019
16 04 2019
Historique:
received:
11
08
2018
accepted:
25
03
2019
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
29
2
2020
Statut:
epublish
Résumé
The global malaria burden has decreased over the last decade and many nations are attempting elimination. Asymptomatic malaria infections are not normally diagnosed or treated, posing a major hurdle for elimination efforts. One solution to this problem is mass drug administration (MDA), with success depending on adequate population participation. Here, we present a detailed spatial and temporal analysis of malaria episodes and asymptomatic infections in four villages undergoing MDA in Myanmar. In this study, individuals from neighborhoods with low MDA adherence had 2.85 times the odds of having a malaria episode post-MDA in comparison to those from high adherence neighborhoods, regardless of individual participation, suggesting a herd effect. High mosquito biting rates, living in a house with someone else with malaria, or having an asymptomatic malaria infection were also predictors of clinical episodes. Spatial clustering of non-adherence to MDA, even in villages with high overall participation, may frustrate elimination efforts.
Identifiants
pubmed: 30990166
doi: 10.7554/eLife.41023
pii: 41023
pmc: PMC6467567
doi:
pii:
Substances chimiques
Antimalarials
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome
ID : 101148/Z/13/Z
Pays : International
Organisme : Bill and Melinda Gates Foundation
ID : OPP1081420
Pays : International
Informations de copyright
© 2019, Parker et al.
Déclaration de conflit d'intérêts
DP, ST, LW, LK, MT, JL, VC, VC, AD, Lv, NW, RM, FN No competing interests declared
Références
Lancet Infect Dis. 2018 May;18(5):565-572
pubmed: 29398388
Infect Drug Resist. 2018 Mar 01;11:299-306
pubmed: 29535546
Malar J. 2015 Sep 30;14:381
pubmed: 26424000
Malar J. 2016 Nov 25;15(1):571
pubmed: 27887652
Trials. 2018 Oct 16;19(1):558
pubmed: 30326952
Vaccine. 2015 Jul 31;33(32):3795-800
pubmed: 26116250
Eur J Epidemiol. 2000;16(7):601-6
pubmed: 11078115
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
Malar J. 2013 Jun 13;12:203
pubmed: 23764006
J Infect Dis. 2017 Feb 1;215(3):396-404
pubmed: 27932615
Malar J. 2011 Aug 24;10:247
pubmed: 21864343
PLoS One. 2014 Dec 23;9(12):e116063
pubmed: 25536053
PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2562
pubmed: 24340111
Rev Bras Malariol Doencas Trop. 1955 Jan;7(1):5-23
pubmed: 13290132
Cochrane Database Syst Rev. 2013 Dec 09;(12):CD008846
pubmed: 24318836
Clin Infect Dis. 2019 Jul 2;69(2):278-286
pubmed: 30304511
Wellcome Open Res. 2017 Sep 6;2:81
pubmed: 29062913
Malar J. 2018 Nov 3;17(1):405
pubmed: 30390647
J Clin Microbiol. 2014 Sep;52(9):3303-9
pubmed: 24989601
Lancet. 2013 Sep 7;382(9895):900-11
pubmed: 23594387
Wellcome Open Res. 2017 Dec 22;2:98
pubmed: 29384151
PLoS Med. 2017 Feb 7;14(2):e1002224
pubmed: 28170391
Nature. 2002 Jul 18;418(6895):320-3
pubmed: 12124623